Arnaud Autret
Principal @ Illumina Ventures
Paris, France
Arnaud Autret is a Series A investor at Illumina Ventures in Paris focused on Biotechnology and Medical. Arnaud joined Seventure Partners Life Sciences team in January 2014.Previously, he worked for the Institut Pasteur and at Trinity College in Dublin as Head of R&D in Virology and Cancer.Prior to this, he worked as a Financial Auditor at KPMG Audit in the Healthcare sector for three years.Arnaud is a Doctor in Biology and Virologyfrom the Institut Pasteur. He has a Master’s Degree in Audit and Consulting from ESCP.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Arnaud Autret invests in
Stages Arnaud Autret invests in
Countries Arnaud Autret invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Pre-Seed 1 (25%)
Country
- United Kingdom 2 (50%)
- France 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Broken String Biosciences
|
Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | $15M / Series A / Sep 18, 2023 | |
NanoSyrinx
|
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | $8.5M / Seed / Jul 19, 2021 | |
|
NanoSyrinx
|
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | Pre-Seed / Sep 30, 2020 | |
Scipio Bioscience
|
Scipio Bioscience, a Paris-based biotechnology company, provides a novel sample preparation solutionfor single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics. | $6.5M / Series A / Feb 25, 2020 |
Co-Investors
About Illumina Ventures
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world's leading genomics solutions provider.They invest primarily in early stage companies, in areas where their expertise and special relationshipwith Illumina can add value. They typically syndicate with other leading institutional and strategic investors.Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.
Illumina Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Arnaud Autret
Principal
|
|||
Donal D. Delaney
Chief Financial Officer
|
|||
Judy Koh
CFO
|
|||
Nicholas Naclerio
Founding Partner
|
|||
Suresh Pisharody
Entrepreneur In Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arnaud Autret invest in?
Arnaud Autret invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Arnaud Autret last invest?
The most recent investment recorded for Arnaud Autret closed in Sep 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
